Comparative Pharmacology
Head-to-head clinical analysis: ALOSETRON HYDROCHLORIDE versus ONDANSETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOSETRON HYDROCHLORIDE versus ONDANSETRON.
ALOSETRON HYDROCHLORIDE vs Ondansetron
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alosetron is a selective antagonist of the serotonin 5-HT3 receptor. By blocking 5-HT3 receptors in the gastrointestinal tract and central nervous system, it reduces visceral hypersensitivity, colonic motility, and intestinal secretions, thereby alleviating symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D).
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing nausea and vomiting.
1 mg orally twice daily for 4 weeks; if response is inadequate, increase to 1 mg twice daily for an additional 4 weeks.
8 mg orally or intravenously every 8 hours as needed, or 32 mg IV single dose prior to chemotherapy; maximum 24 mg IV single dose for prevention of postoperative nausea and vomiting.
None Documented
None Documented
Clinical Note
moderateOndansetron + Norfloxacin
"Ondansetron may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateOndansetron + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Ondansetron is combined with Fluticasone propionate."
Clinical Note
moderateOndansetron + Haloperidol
"Ondansetron may increase the QTc-prolonging activities of Haloperidol."
Clinical Note
moderateOndansetron + Ibandronate
Terminal half-life is approximately 1.5–2 hours in healthy volunteers; prolonged in hepatic impairment (up to 2.5 hours) but no significant accumulation with repeated dosing.
Terminal elimination half-life is approximately 3-6 hours in adults; may be prolonged to 8-15 hours in elderly or severe hepatic impairment (Child-Pugh Class C).
Renal: ~73% (mostly as metabolites), Fecal: ~24%, Biliary: minor; <1% excreted unchanged in urine.
Approximately 5% of the dose is excreted unchanged in urine, while the majority is metabolized hepatically via CYP1A2, CYP2D6, and CYP3A4. About 90% is eliminated as metabolites in urine (48%) and feces (42%).
Category C
Category C
5-HT3 Antagonist
5-HT3 Antagonist
"Ondansetron may increase the QTc-prolonging activities of Ibandronate."